Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

04.08.22	Eli Lilly And Co. Profit Declines In Q2 (RTTNews)
04.08.22	Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements (PR Newswire)
21.07.22	Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement (PR Newswire)
29.06.22	Lilly To Supply Addl. 150K Doses Of Bebtelovimab To U.S. Government For About $275 Mln (RTTNews)
29.06.22	Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options (PR Newswire)
27.06.22	Lilly Declares Third-Quarter 2022 Dividend (PR Newswire)
27.06.22	Statement of changes in beneficial ownership of securities (RSS)
27.06.22	Lilly : China Approves TYVYT Combination For Treatment Of Gastric Cancer (RTTNews)
24.06.22	Statement of changes in beneficial ownership of securities (RSS)
23.06.22	Statement of changes in beneficial ownership of securities (RSS)
21.06.22	Innovent : China Approves TYVYT Combination As Treatment For Esophageal Squamous Cell Carcinoma (RTTNews)
14.06.22	FDA Approves First Medicine Ever For Alopecia Areata (RTTNews)
14.06.22	FDA Approves Lilly's Olumiant As First Systemic Treatment For Alopecia (RTTNews)
14.06.22	FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata (PR Newswire)
07.06.22	Lilly Reports Positive Data From Lebrikizumab Atopic Dermatitis Monotherapy Trials (RTTNews)
07.06.22	Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials (PR Newswire)
07.06.22	New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions® (PR Newswire)
06.06.22	Lilly : Jardiance Decreases Risk Of Hospitalization For Heart Failure By 50% In Type 2 Diabetes (RTTNews)
05.06.22	Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world eviden... (PR Newswire)
04.06.22	Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo (PR Newswire)
04.06.22	Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight (PR Newswire)
03.06.22	Lilly to Participate in Goldman Sachs Global Healthcare Conference (PR Newswire)
31.05.22	Statement of changes in beneficial ownership of securities (RSS)
26.05.22	Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
26.05.22	Lilly To Invest $2.1 Bln In New Manufacturing Sites In Indiana (RTTNews)
25.05.22	Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana (PR Newswire)
25.05.22	Statement of changes in beneficial ownership of securities (RSS)
24.05.22	Lilly: One-half Of Mirikizumab Patients Achieves Clinical Remission At One Year In Phase 3 Study (RTTNews)
24.05.22	Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study (PR Newswire)
23.05.22	Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA (PR Newswire)
20.05.22	Lilly : CHMP Issues Positive Opinion For Olumiant For Severe Alopecia Areata Treatment (RTTNews)
20.05.22	CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA) (PR Newswire)
19.05.22	Statement of changes in beneficial ownership of securities (RSS)
18.05.22	Statement of changes in beneficial ownership of securities (RSS)
17.05.22	Statement of changes in beneficial ownership of securities (RSS)
16.05.22	Lilly to Participate in UBS Global Healthcare Conference 2022 (PR Newswire)
14.05.22	FDA Approves Lilly's Mounjaro Injection For Type 2 Diabetes Treatment (RTTNews)
13.05.22	FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes (PR Newswire)
11.05.22	Eli Lilly, Incyte Announce FDA Approval Of OLUMIANT For Hospitalized Patients With COVID-19 (RTTNews)
11.05.22	FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 (PR Newswire)
06.05.22	Mary Lynne Hedley Elected to Lilly Board of Directors (PR Newswire)
03.05.22	Lilly to Participate in Bank of America Securities 2022 Healthcare Conference (PR Newswire)
02.05.22	Lilly Declares Second-Quarter 2022 Dividend (PR Newswire)
28.04.22	Lilly: Tirzepatide In SURMOUNT-1 Trial Delivers Superior Weight Loss In Adults (RTTNews)
28.04.22	Eli Lilly Q1 Results Top Estimates; Boosts FY22 Revenue Outlook (RTTNews)
28.04.22	Eli Lilly And Co. Reveals Increase In Q1 Profit (RTTNews)
28.04.22	Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022 (PR Newswire)
28.04.22	Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 (PR Newswire)
20.04.22	Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care (PR Newswire)
19.04.22	Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

29.12.24		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Börse Frankfurt: DAX zum Handelsende auf grünem Terrain
27.12.24		Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester
27.12.24		Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
27.12.24		Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge
27.12.24		SLI-Handel aktuell: Zum Handelsende Gewinne im SLI

29.12.24

Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen

27.12.24

Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus

27.12.24

BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester

27.12.24

Börse Frankfurt: DAX zum Handelsende auf grünem Terrain

27.12.24

Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester

27.12.24

Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen

27.12.24

Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge

27.12.24

SLI-Handel aktuell: Zum Handelsende Gewinne im SLI

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Eli Lilly

Aktien Top/Flop

Eli Lilly Peer Group Nachrichten

Meistgelesene Nachrichten